Fed. Circ. To Weigh In On Written Description Rule

Law360, New York (October 07, 2009, 5:00 PM ET) -- In a case that could make patents easier to prosecute and tougher to invalidate, a federal appeals court is gearing up for an en banc rehearing of Ariad Pharmaceuticals Inc.’s patent infringement fight against Eli Lilly & Co. over osteoporosis drug Evista and septic shock treatment Xigris.

The U.S. Court of Appeals for the Federal Circuit in August granted Ariad’s request for a rehearing and asked the parties to brief the court on whether an inventor can obtain a patent by enabling someone with skill in...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers